Eli Lilly and Co.

Life sciences panel pegs bright spots in IndianaRestricted Content

August 14, 2010
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
More

Eli Lilly loses patent lawsuit for Strattera

August 13, 2010
 IBJ Staff and Associated Press
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
More

For Lilly, it's a big one that got away

August 11, 2010
J.K. Wall
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with analysts predicting as much as $2 billion in annual U.S. sales.
More

Court defeat lost in Lilly's gloomy long-term outlook

August 9, 2010
J.K. Wall
Eli Lilly and Co.'s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn from investors, who have shunned the stock because of five looming patent expirations.
More

Lilly among bidders for Denmark company, source says

July 30, 2010
Bloomberg News
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said. Ascendis may choose a final bidder by early September.
More

Lilly loses appeal over patent for cancer drug Gemzar

July 28, 2010
 IBJ Staff and Bloomberg News
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013. Gemzar generated $1.36 billion in global sales in 2009.
More

Lilly's second-quarter profits surge 16 percent

July 22, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months ended June 30, even after paying $27 million in severance to laid off employees.
More

Lilly completes $180 million acquisition of Alnara

July 21, 2010
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company developing an enzyme-replacement therapy for disorders of the pancreas.
More

New rules raise stakes for Lilly drug

July 21, 2010
J.K. Wall
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses of the disease.
More

Lilly reveals plans to cut 340 IT jobs

July 15, 2010
J.K. Wall
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115 cuts will be made this month, and the remainder by the end of the year.
More

Lilly, Roche dive deep into diagnostics

July 14, 2010
J.K. Wall
Two Indianapolis giants—Eli Lilly and Co. and Roche Diagnostics—are working hard to pair up drugs and diagnostic tests to gin up more sales.
More

Lilly's Alzheimer's gamble takes aim at $10 billion in patent losses

July 13, 2010
Bloomberg News
Both of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more than $5 billion a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
More

Lilly to cut 170 manufacturing jobs by year's end

July 12, 2010
J.K. Wall
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling drugs.
More

Diagnostics division to help Lilly tailor treatmentsRestricted Content

July 10, 2010
J.K. Wall
Eli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit from a Lilly drug.
More

Lilly's Lechleiter: No change in plans

July 7, 2010
J.K. Wall
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no mega-merger.
More

Men on Viagra, Cialis show triple rate of sex diseases in study

July 6, 2010
 IBJ Staff and Bloomberg News
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly's Cialis, may be more likely to engage in unsafe sex than nonusers.
More

Lilly acquires biotech company with pancreatic drug

July 2, 2010
J.K. Wall
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years, recently submitted its drug to the FDA for market approval.
More

Grassley asks Lilly, peers about whistleblower treatment

July 1, 2010
Bloomberg News
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal how they treat whistleblowers who file complaints under the False Claims Act.
More

Lilly's Effient steps forward, then back

June 30, 2010
J.K. Wall
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor, Plavix, a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
More

Marcadia enlists Lilly to help develop new diabetes drug

June 28, 2010
J.K. Wall
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s current Glucagon for patients with severe hypoglycemia.
More

Hoosier firms that rely on innovation pine for patent reform

June 26, 2010
J.K. Wall
One key change would grant patents to the first inventor to file an application, not the first who can prove to have made the invention first.
More

Lilly layoffs pare communications department

June 21, 2010
J.K. Wall
The giant drugmaker is in the process of trimming 35 percent—or about 19 people—from its 55-person communications staff. Most of that staff is based in Indianapolis.
More

Recession hammered revenue of Indiana's largest public companies

June 19, 2010
Marc D. Allan
Few escaped the Great Recession unscathed, and unusual circumstances helped some appear as though they did.
More

Slow economy bruises profits of Indiana's largest public companiesRestricted Content

June 19, 2010
Marc D. Allan
One-time events influenced bottom lines of some of the few companies that made more money in 2009.
More

Lilly, Amylin stock rises on drug postponement

June 18, 2010
 IBJ Staff and Bloomberg News
Roche Holding AG's decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals Inc. and drug partner Eli Lilly and Co.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT